$VKTX 0.57 Developing

Notable posts

• @StockSavvyShay neutral 664 eng

  NEXT WEEKS EARNINGS ARE MASSIVE • Monday | $APLD, $NVTS, $CDNS, $AMKR • Tuesday | $BE, $KLAC, $PYPL, $V, $TER, $ENPH • Wednesday | $MSFT, $META, $HOOD, $ARM, $QCOM, $SOFI, $VRT, $LMND, $LRCX, $VKTX, $FTNT, $CVNA • Thursday | $AAPL, $AMZN, $COIN, $RBLX, $RDDT, $TEM, $RIVN, $FSLR, $MA, $PGY, $MSTR, $AXTI, $NXT • FRIDAY | $CVX, $XOM, $ABBV, $CCJ, $MRNA

  view on X →
• @StockSavvyShay bullish 321 eng

  $VKTX is up 42% after VK2735 maintained up to 97% of prior weight loss on every-other-week dosing and ~90% on monthly dosing. That dosing flexibility is a real differentiator as VK2735 moves through Phase 3 with patients still losing weight at week 33 and no plateau observed. https://t.co/aejm5aWaS8

  view on X →
• @wallstengine neutral 240 eng

  $VKTX OBESITY DRUG MAINTAINS MOST WEIGHT LOSS WITH LESS-FREQUENT DOSING Viking Therapeutics says VK2735 maintained up to 97% of prior weight loss when patients moved from weekly injections to every-other-week dosing, and up to 90% with monthly dosing over 12 weeks. Before the maintenance phase, patients had lost roughly 16%-19% of body weight over 21 weeks. An exploratory group that stayed on weekly 17.5 mg dosing reached about 22% weight loss by week 33, with no plateau observed. GI side effects during maintenance were similar to placebo, and discontinuations remained low. Viking plans to test oral maintenance dosing next. VK2735 is already in Phase 3 development for obesity.

  view on X →
• @enrichtrades bullish 159 eng

  Watchlist for tomorrow, 7/8: Momentum is still there. Stay patient. Don't overtrade. One A+ setup is all you need. 7 straight winning trades. Recent: $IBM +370% $LLY +200% Watching: $DELL $IBM $PLTR $UBER $META Healthcare: $LLY $TEM $VKTX $UNH $OSCR Let price action confirm. React, don't predict. Preserve your capital and let the leaders do the heavy lifting.

  view on X →
• @ripster47 bullish 101 eng

  $VKTX 🚨 Setting up for Weekly Breakout Soon for push to 50 Now De-Risked Position with Solid Data Yesterday Thanks to @Pharmdca Our long from 30 looking pretty good now https://t.co/FAWYqsdsE7

  view on X →
• @ripster47 neutral 97 eng

  $VKTX Offering Completed 🚨 Completed a $500 million capital raise through a two-part offering, with one investor acquiring approximately one-third of the shares in the upsized equity portion, Bloomberg reported Thursday. The obesity drug developer raised $275 million through a stock offering and an additional $225 million from the sale of six-year convertible bonds, according to a company statement. The stock offering drew demand for several times the available shares after being increased in size, according to people familiar with the matter who requested anonymity. More than 75% of the offering was allocated to 10 investors, the people said.

  view on X →
• @StockSavvyShay bullish 82 eng

  FUTURUM EQUITIES PODCAST EPISODE #58 Daniel and I will be live today at 1PM ET exclusively on the Futurum Equities YouTube channel covering • Why $META could keep rerating toward $850 as Muse turns AI spending into a real consumer product and new monetization layer • Why $AMD is running harder than $NVDA • What we're watching from $MU earnings next week • Why AI Power could become one of the biggest themes of 2027 across $GEV, $VRT, $ON, $BE, $FPS and $NVTS • Why latest $VKTX maintenance data materially improves the commercial case for VK2735 We’ll leave the last 20-30minutes for live Q&A so bring your questions.

  view on X →
• @ripster47 bullish 65 eng

  $VKTX Position down from highs due to Arbitrage Shorts & and technicalsl. From 43 to 31, Cash position & story got only better! Great R/R I encourage All Investors go through our Research https://t.co/Y9VVNbLD5f Still Best in Class, overtime Price will respond as Technical improve.

  view on X →